<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748253</url>
  </required_header>
  <id_info>
    <org_study_id>0067</org_study_id>
    <nct_id>NCT01748253</nct_id>
  </id_info>
  <brief_title>ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)</brief_title>
  <acronym>ACROBAT</acronym>
  <official_title>ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acrobat Trial Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acrobat Trial Group</source>
  <brief_summary>
    <textblock>
      Evaluation of 24-hour antihypertensive effect of long-acting ARB-CCB tablet administrated to
      hypertensive patients with atrial fibrillation, and comparison of 24-hour antihypertensive
      effect of long-acting ARB-CCB tablet between morning administration and bedtime
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour average blood pressure from baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressures at night time, early-morning, and daytime from baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure at hospital visit from baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure at home from baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure control rate from baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure variability from baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (blood insulin, hsTnT, PAI-1, and NT-ProBNP) from baseline to Week 12.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Adverse events</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of atrial fibrillation</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PWV value</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory test results</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertension and Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Telmisartan-amlodipine tablet administration group (morning)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan-amlodipine tablet administration group (bedtime)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan-amlodipine tablet administration group (morning)</intervention_name>
    <description>Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks</description>
    <arm_group_label>Telmisartan-amlodipine tablet administration group (morning)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan-amlodipine tablet administration group (bedtime)</intervention_name>
    <description>Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks</description>
    <arm_group_label>Telmisartan-amlodipine tablet administration group (bedtime)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hypertensive patients who meet the following conditions:

             Patients who meet any of the following standards of blood pressure after
             administration of 40 mg/day telmisartan or 5 mg/day amlodipine for 4 weeks:

             - Blood pressure at hospital visit: Systolic blood pressure is 140 mmHg or higher,
             and/or diastolic blood pressure is 90 mmHg or higher.

             (average of 3 measurements obtained at a scheduled visit)

             - Blood pressure at home: Systolic blood pressure is 135 mmHg or higher, and/or
             diastolic blood pressure is 85 mmHg or higher.

             (average of measurements for the 5 days prior to drug assignment [4 measurements per
             day in total: 2 in the morning and 2 before bedtime])

          2. Patients with atrial fibrillation detected on an electrocardiogram within the last 2
             years prior to obtaining informed consent.

          3. Age: 20 years old or older (at time of informed consent)

          4. Sex: male or female

          5. Clinical classification: Outpatient

          6. Patients who give written consent of agreement to voluntarily participate in the
             clinical study.

        Exclusion Criteria:

          1. Patients with serious liver and/or kidney disease

          2. Patients with history of allergy to telmisartan or amlodipine

          3. Patients receiving antihypertensives other than telmisartan or amlodipine during
             observation period

          4. Patients diagnosed with persistent atrial fibrillation or chronic (permanent) atrial
             fibrillation.

          5. Patients with atrial fibrillation caused by irreversible illness (e.g., heart surgery,
             pulmonary embolism, or hyperthyroidism)

          6. Patients with average systolic blood pressure at hospital visit higher than 180 mmHg
             during observation period.

          7. Patients with New York Heart Association (NYHA) class III-IV heart failure, patients
             with heart failure requiring hospitalization, or patients with poor left ventricular
             function.

          8. Patients who have stroke or cardiac infarction within 6 months before giving consent.

          9. Patients planning to undergo pulmonary artery ablation surgery or any surgical
             procedure (including PCI).

         10. Patients who are breast-feeding, pregnant, possibly pregnant, or plan to become
             pregnant.

         11. In addition, patients who are determined as not eligible by their study doctor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuomi Kario</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shinji Mitoma</last_name>
    <phone>+81-3-5312-5026</phone>
    <email>acrobat-study@sa-tt.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uchiyama Clinic</name>
      <address>
        <city>Joetsu city</city>
        <state>Niigata pref.</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuaki Uchiyama</last_name>
      <phone>+81‐25‐548‐2400</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

